A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs AMV 564 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amphivena Therapeutics
- 31 May 2018 Status changed from not yet recruiting to recruiting.
- 24 Apr 2018 Status changed from planning to not yet recruiting.
- 12 Sep 2017 New trial record